Prokidney to participate in the morgan stanley 22nd annual global healthcare conference

Winston-salem, n.c., aug. 27, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (ckd), today announced that senior members of the management team will be participating in the morgan stanley 22nd annual global healthcare conference, being held in new york, ny on september 4-6, 2024.
PROK Ratings Summary
PROK Quant Ranking